HC Wainwright Reaffirms "Neutral" Rating for OptiNose (NASDAQ:OPTN)

OptiNose (NASDAQ:OPTN - Get Free Report)'s stock had its "neutral" rating reissued by HC Wainwright in a note issued to investors on Friday, MarketBeat.com reports. They currently have a $9.00 price target on the stock, down from their previous price target of $18.00. HC Wainwright's price objective indicates a potential downside of 1.85% from the company's previous close.

Separately, Lake Street Capital downgraded OptiNose from a "buy" rating to a "hold" rating and lowered their price target for the company from $17.00 to $9.00 in a report on Thursday, March 20th.

OptiNose Price Performance

Shares of OPTN stock remained flat at $9.17 on Friday. 110,638 shares of the company were exchanged, compared to its average volume of 61,032. The stock has a market cap of $92.25 million, a P/E ratio of -2.18 and a beta of -0.30. The company's fifty day moving average price is $6.04 and its 200 day moving average price is $8.04. OptiNose has a 12-month low of $4.82 and a 12-month high of $23.55.

Insiders Place Their Bets

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. The trade was a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 8,213 shares of company stock valued at $43,643. 2.30% of the stock is currently owned by insiders.

Remove Ads

Hedge Funds Weigh In On OptiNose

Institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new position in OptiNose during the 3rd quarter worth $61,000. State Street Corp grew its holdings in shares of OptiNose by 14.2% during the third quarter. State Street Corp now owns 341,303 shares of the company's stock worth $229,000 after buying an additional 42,500 shares during the last quarter. Geode Capital Management LLC increased its position in OptiNose by 33.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company's stock valued at $870,000 after acquiring an additional 326,918 shares during the period. Massachusetts Financial Services Co. MA raised its stake in OptiNose by 5.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company's stock valued at $2,061,000 after acquiring an additional 155,329 shares during the last quarter. Finally, Acorn Capital Advisors LLC acquired a new stake in OptiNose during the 4th quarter worth approximately $2,824,000. 85.60% of the stock is owned by institutional investors and hedge funds.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.